vs
CBIZ, Inc.（CBZ）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
CBIZ, Inc.的季度营收约是Royalty Pharma plc的1.4倍（$848.6M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 19.0%，领先15.4%），Royalty Pharma plc同比增速更快（4.8% vs 1.3%），过去两年CBIZ, Inc.的营收复合增速更高（42.1% vs 4.6%）
CBIZ, Inc.是美国知名的金融、保险及咨询服务提供商，总部位于俄亥俄州独立市，为美国规模最大的会计、保险经纪、金融与咨询服务机构之一。集团在全美设有120多个办事处，拥有近7000名员工，1996年起在纽交所上市，1997年起使用股票代码CBZ交易。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CBZ vs RPRX — 直观对比
营收规模更大
CBZ
是对方的1.4倍
$622.0M
营收增速更快
RPRX
高出3.5%
1.3%
净利率更高
RPRX
高出15.4%
19.0%
两年增速更快
CBZ
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $848.6M | $622.0M |
| 净利润 | $161.6M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | 62.4% |
| 净利率 | 19.0% | 34.4% |
| 营收同比 | 1.3% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $2.63 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBZRPRX
| Q1 26 | $848.6M | — | ||
| Q4 25 | $542.7M | $622.0M | ||
| Q3 25 | $693.8M | $609.3M | ||
| Q2 25 | $683.5M | $578.7M | ||
| Q1 25 | $838.0M | $568.2M | ||
| Q4 24 | $460.3M | $593.6M | ||
| Q3 24 | $438.9M | $564.7M | ||
| Q2 24 | $420.0M | $537.3M |
净利润CBZRPRX
| Q1 26 | $161.6M | — | ||
| Q4 25 | $-79.4M | $214.2M | ||
| Q3 25 | $30.1M | $288.2M | ||
| Q2 25 | $41.9M | $30.2M | ||
| Q1 25 | $122.8M | $238.3M | ||
| Q4 24 | $-90.7M | $208.2M | ||
| Q3 24 | $35.1M | $544.0M | ||
| Q2 24 | $19.8M | $102.0M |
毛利率CBZRPRX
| Q1 26 | — | — | ||
| Q4 25 | -9.4% | — | ||
| Q3 25 | 13.0% | — | ||
| Q2 25 | 12.9% | — | ||
| Q1 25 | 27.2% | — | ||
| Q4 24 | -13.4% | — | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | 12.8% | — |
营业利润率CBZRPRX
| Q1 26 | 23.2% | — | ||
| Q4 25 | -15.7% | 62.4% | ||
| Q3 25 | 8.5% | 70.1% | ||
| Q2 25 | 8.8% | 36.3% | ||
| Q1 25 | 23.9% | 94.0% | ||
| Q4 24 | -23.2% | 60.9% | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 7.5% | 50.2% |
净利率CBZRPRX
| Q1 26 | 19.0% | — | ||
| Q4 25 | -14.6% | 34.4% | ||
| Q3 25 | 4.3% | 47.3% | ||
| Q2 25 | 6.1% | 5.2% | ||
| Q1 25 | 14.7% | 41.9% | ||
| Q4 24 | -19.7% | 35.1% | ||
| Q3 24 | 8.0% | 96.3% | ||
| Q2 24 | 4.7% | 19.0% |
每股收益（稀释后）CBZRPRX
| Q1 26 | $2.63 | — | ||
| Q4 25 | $-1.22 | $0.49 | ||
| Q3 25 | $0.48 | $0.67 | ||
| Q2 25 | $0.66 | $0.07 | ||
| Q1 25 | $1.91 | $0.55 | ||
| Q4 24 | $-1.84 | $0.46 | ||
| Q3 24 | $0.70 | $1.21 | ||
| Q2 24 | $0.39 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.7M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.9B | $9.7B |
| 总资产 | $4.6B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CBZRPRX
| Q1 26 | $28.7M | — | ||
| Q4 25 | $18.3M | $618.7M | ||
| Q3 25 | $17.0M | $938.9M | ||
| Q2 25 | $39.8M | $631.9M | ||
| Q1 25 | $8.8M | $1.1B | ||
| Q4 24 | $13.8M | $929.0M | ||
| Q3 24 | $1.1M | $950.1M | ||
| Q2 24 | $1.1M | $1.8B |
总债务CBZRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益CBZRPRX
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $9.7B | ||
| Q3 25 | $1.9B | $9.6B | ||
| Q2 25 | $1.9B | $9.5B | ||
| Q1 25 | $1.9B | $9.8B | ||
| Q4 24 | $1.8B | $10.3B | ||
| Q3 24 | $927.9M | $10.3B | ||
| Q2 24 | $891.4M | $9.8B |
总资产CBZRPRX
| Q1 26 | $4.6B | — | ||
| Q4 25 | $4.4B | $19.6B | ||
| Q3 25 | $4.5B | $19.3B | ||
| Q2 25 | $4.5B | $18.3B | ||
| Q1 25 | $4.6B | $17.6B | ||
| Q4 24 | $4.5B | $18.2B | ||
| Q3 24 | $2.1B | $18.0B | ||
| Q2 24 | $2.2B | $17.7B |
负债/权益比CBZRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-25.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-28.5M | — |
| 自由现金流率自由现金流/营收 | -3.4% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -0.16× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $240.5M | — |
8季度趋势，按日历期对齐
经营现金流CBZRPRX
| Q1 26 | $-25.5M | — | ||
| Q4 25 | $143.6M | $827.1M | ||
| Q3 25 | $24.0M | $702.6M | ||
| Q2 25 | $113.1M | $364.0M | ||
| Q1 25 | $-88.3M | $596.1M | ||
| Q4 24 | $55.5M | $742.5M | ||
| Q3 24 | $43.7M | $703.6M | ||
| Q2 24 | $88.2M | $658.2M |
自由现金流CBZRPRX
| Q1 26 | $-28.5M | — | ||
| Q4 25 | $141.7M | — | ||
| Q3 25 | $22.1M | — | ||
| Q2 25 | $105.2M | — | ||
| Q1 25 | $-93.4M | — | ||
| Q4 24 | $52.3M | — | ||
| Q3 24 | $41.1M | — | ||
| Q2 24 | $86.3M | — |
自由现金流率CBZRPRX
| Q1 26 | -3.4% | — | ||
| Q4 25 | 26.1% | — | ||
| Q3 25 | 3.2% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | -11.2% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 9.4% | — | ||
| Q2 24 | 20.5% | — |
资本支出强度CBZRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.4% | — |
现金转化率CBZRPRX
| Q1 26 | -0.16× | — | ||
| Q4 25 | — | 3.86× | ||
| Q3 25 | 0.79× | 2.44× | ||
| Q2 25 | 2.70× | 12.06× | ||
| Q1 25 | -0.72× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.25× | 1.29× | ||
| Q2 24 | 4.45× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBZ
| Financial Services (1) | $740.3M | 87% |
| Benefits and Insurance Services | $108.2M | 13% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
